Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 30, 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific transaction notification and does not contain financial statements or performance metrics.
Material Changes
The filing reports a specific increase in the notional allocation of GSK American Depositary Shares (ADSs) within the GSK 401K plan. This change resulted from the revaluation of the cash element of the notional investment held within the plan on March 27, 2015.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction noted.
Important Facts for Investors
- Transaction Date: March 27, 2015 (notified March 30, 2015).
- Transaction Type: Increase in notional allocation of GSK ADSs within the 401K plan due to cash element revaluation.
- Price: $47.02 per ADS.
- Connected Person: Dr K Slaoui (connected person of Dr M M Slaoui).
- Quantity: 10 ADSs.
- Signatory: Victoria Whyte, Company Secretary.